NCT00389610View on ClinicalTrials.gov

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 11, 2006

Primary Completion Date

October 11, 2021

Study Completion Date

December 10, 2022

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

GVAX pancreas vaccine

Given intradermally

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

The Skip Viragh Foundation

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00389610 - Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter